Abstracts tagged "pulmonary complications and systemic lupus erythematosus (SLE)"

Abstract Number: 772 • 2018 ACR/ARHP Annual Meeting
Cytomegaloviral or Pneumocystis Jiroveci Pneumonia Increases Mortality Rate in Systemic Lupus Erythematosus Patients with Pulmonary Hemorrhage: Evidence from Bronchoalveolar Lavage Fluid Analysis
Chien-Chih Lai, Yi-Syuan Sun and De-Feng Huang, Allergy, Immunology, Rheumatology, Taipei Veterans General Hospital, Taiwan, Taipei City, Taiwan
Background/Purpose: To evaluate the role of cytomegaloviral or Pneumocystic jiroveci pneumonia (CMV/PJP) in SLE patients with pulmonary hemorrhage (PH).Methods: We retrospectively examined hospital records for…
Abstract Number: 2090 • 2018 ACR/ARHP Annual Meeting
Identification of a Role for Monocytes in Murine Lupus Associated Diffuse Alveolar Hemorrhage By Mass Cytometry
Nathan Nelson-Maney¹, Pui Lee², Anais Levescot³, Yuelong Huang⁴ and Peter Nigrovic⁵, ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication of systemic lupus erythematosus. The inciting pathology is thought to be pulmonary capillaritis but the…
Abstract Number: 1780 • 2016 ACR/ARHP Annual Meeting
Pulmonary Disease in Late Versus Early Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Jennifer Medlin¹, Karen Hansen², Sara McCoy³ and Christie M. Bartels⁴, ¹Internal Medicine, University of Wisconsin Hospitals and Clinics, Madison, WI, ²Department of Medicine, Division of Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ³Department of Medicine, Rheumatology Division, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Phenotypes often differ in late-onset systemic lupus erythematosus (SLE) compared to SLE features in early-onset patients. Prior studies have suggested that there may be…
Abstract Number: 1804 • 2016 ACR/ARHP Annual Meeting
Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: a Single Centre Experience
Konstantinos Tselios¹, Dafna D Gladman² and Murray Urowitz³, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Pulmonary arterial hypertension (PAH) is detected in 0.5-17.5% of patients with systemic lupus erythematosus (SLE). Systemic inflammation may play a dominant role in its…
Abstract Number: 595 • 2013 ACR/ARHP Annual Meeting
Anemic Hypoxia Is Associated With Pulmonary Arterial Hypertension In Patients With Systemic Lupus Erythematosus
Ki-Jo Kim¹, In-Woon Baek², Chong-Hyeun Yoon³, Jin-Jung Choi⁴, Wan-Uk Kim² and Chul-Soo Cho⁵, ¹Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Suwon, South Korea, ²Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, South Korea, ⁴Internal Medicine, CHA University Hospital, Seongnam, South Korea, ⁵Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Pulmonary arterial hypertension (PAH) is a serious and often fatal complication of systemic lupus erythematosus (SLE), but its pathogenesis is still unclear. Hypoxia-induced pulmonary…
Abstract Number: 683 • 2012 ACR/ARHP Annual Meeting
Prevalence of Inhibitory or Non-Inhibitory Autoantibodies to Angiotensin Converting Enzyme 2 (ACE2) in Patients with Systemic Lupus Erythematosus
Yuko Takahashi¹, Shiori Haga², Yukihito Ishizaka² and Akio Mimori³, ¹Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan, ²Department of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan, ³Department of Intractable Diseases, National Center for Global Health and Medicine, Tokyo, Japan
Background/Purpose: We previously reported that inhibitory autoantibodies to angiotensin converting enzyme 2 (ACE2) predisposed individuals to connective tissue diseases (i.e., scleroderma or systemic lupus erythematosus…
Abstract Number: 644 • 2012 ACR/ARHP Annual Meeting
Pulmonary Hypertension in Systemic Lupus Erythematosus: A 6-Year Follow-up Study Cohort
Claudia Hübbe-Tena¹, Selma Gallegos-Nava¹, Rafael Bojalil² and Luis M. Amezcua-Guerra¹, ¹Rheumatology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ²Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) may present hemodynamic alterations including pulmonary hypertension (PH). Echocardiography (ECHO) is a noninvasive imaging technique useful to classify pulmonary hypertension…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].